Special Issue

Innovative Immunotherapies: CAR-T Cell Therapy for Cancers

Message from the Guest Editor

Dear colleagues, Immunotherapy harnesses the power of the immune system to recognize and attack cancer cells. Innovative immunotherapies, such as CAR-T, have shown advantageous outcomes in various cancer types. By modifying a patient's T cells, CAR-T targets specific antigens in the cancer cells. This precision targeting allows for a particular attack on cancer cells while minimizing damage to healthy cells. However, it is important to note that CAR-T therapy has some encumbrances and challenges. For example, it can be associated with significant side effects, including cytokine release syndrome and neurotoxicity. Improving CAR-T involves better target selection, higher potency, longer persistency, and overcoming resistance mechanisms that are employed by the cancer cells to evade/escape the immune system. In this Special Issue, we will encourage novel approaches and perspectives of CAR-T cell therapy for cancers.

Guest Editor

Dr. Shebli Atrash

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC 28204, USA

Deadline for manuscript submissions

closed (13 December 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/173596

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)